| Detected | Trial | Change |
|---|---|---|
| 2026-08-13 | NCT07291895 High Dose Radiotherapy for Palliation (Hi-D) |
Primary endpoint(s) modified |
| 2026-08-13 | NCT07291895 High Dose Radiotherapy for Palliation (Hi-D) |
Trial arms changed: 2 -> 1 |
| 2026-08-13 | NCT07291895 High Dose Radiotherapy for Palliation (Hi-D) |
date change Primary completion pushed: 2029-06-01 -> 2030-07-01 |
| 2026-08-13 | NCT07291895 High Dose Radiotherapy for Palliation (Hi-D) |
date change Completion pushed: 2029-08-31 -> 2030-08-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT02692105 | Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate… | Prostate Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT04787289 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in… | Ovarian Cancer | Recruiting |
| NCT05050929 | RAPid SimPLE Targeted Radiation Treatment for Brain Metastases | Brain Metastases, Adult | Recruiting |
| NCT06665178 | Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in… | Breast Cancer | Recruiting |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates… | Breast Cancer | Recruiting |
| NCT06835725 | Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative… | Prostate CA | Recruiting |
| NCT03917082 | Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer | Breast Cancer Female | Active, Not Recruiting |
| NCT06650709 | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study | Ovarian Cancer Stage IV | Not Yet Recruiting |
| NCT03769103 | Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive… | Lung Cancer Non-small Cell Stage IV | Active, Not Recruiting |
| NCT06862323 | Time Restricted Eating in Haematological Malignancies | Cancer | Not Yet Recruiting |
| NCT04015622 | PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | Metastatic Castration-resistant Prostate Cancer | Enrolling by Invitation |
| Phase 1 | |||
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | B-Cell Leukemia | Recruiting |
| Not specified | |||
| NCT03836196 | Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease | Prostate Cancer | Recruiting |
| NCT05025878 | 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients. | Ovarian Cancer | Recruiting |
| NCT06628102 | Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study | Lung Cancer | Recruiting |
| NCT05257967 | CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease | EGFR Activating Mutation | Recruiting |
| NCT02155621 | Personalized Oncogenomics (POG) Program of British Columbia | Metastatic Cancers | Recruiting |
| NCT02869802 | Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by… | Cancer | Recruiting |
| NCT05132244 | Monitoring and Managing Glucose Levels in People With Pancreatic Cancer | Pancreatic Cancer | Recruiting |
| NCT04814095 | PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc | Cancer | Recruiting |
| NCT06242912 | Evidence Development in Cancer Treatment - Real World: PREDiCTrw | Cancer | Recruiting |
| NCT06918951 | Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for… | Oligoprogression | Recruiting |
| NCT06574620 | Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to… | Pancreatic Ductal Adenocarcinoma | Recruiting |
| NCT06200974 | Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier… | Localized Prostate Carcinoma | Recruiting |